Trial Profile
A phase 1 safety study of CIM101 in the patients with metastatic lung cancer who are eligible for treatment with a check point inhibitor
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 13 Jan 2021
Price :
$35
*
At a glance
- Drugs CIM 101 (Primary)
- Indications Lung cancer
- Focus Adverse reactions
- 09 Jan 2021 According to a CiMaas media release, company has received an important stimulus from the Netherlands for this trial.It concerns a loan of 2.4 million euro.
- 09 Jan 2021 According to a CiMaas media release, Dr. Lizza Hendriks, pulmonologist at MUMC +, Maastricht, and her colleague Dr. Berber Piet, pulmonologist at the Radboud University Nijmegen Medical Center, Nijmegen are the investigators for this trial.
- 02 Nov 2019 According to a CiMaas media release, this trial is expected to start in 2020.